List view / Grid view
14 May 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc., announced the submission of supplemental New Drug Applications for once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) to the U.S. Food and Drug Administration...
14 May 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation...
13 May 2014 | By Merck
Merck announced that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products...
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
13 May 2014 | By Astrazeneca
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc. earlier...
13 May 2014 | By Pfizer
Pfizer is publishing a presentation to the shareholders of AstraZeneca on the merits of a combination of the two companies...
12 May 2014 | By TSI
TSI Incorporated, the premier provider of particle counting solutions for life science applications, is pleased to announce the submission of a Type V Drug Master File...
12 May 2014 | By kdm communications
Cresset, innovative provider of computational chemistry software and services, announces its annual user meetings, ‘Field Based Chemistry North America’ and ‘Field Based Chemistry Europe’...
12 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced in August 2011 that the Group company, Kitasato Daiichi Sankyo Vaccine Company Limited, had been selected for the Japanese Ministry of Health, Labour and Welfare’s cell culture vaccine production facility capacity building grant...
12 May 2014 | By Novo Nordisk
Novo Nordisk announced new phase 3 interim data from its guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade...
12 May 2014 | By Merck
ZONTIVITY added to standard of care demonstrated long-term benefit through three years...
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
12 May 2014 | By Abbott
Early study results suggest Abbott technology equivalent to current standard of care, but produces results much more quickly...
12 May 2014 | By European Pharmaceutical Review
European Drug Target Review is a business-to-business magazine featuring the latest developments in drug discovery and new drug development collaborations...
